Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Addition of Absolute Lymphocytes/Monocytes Ratio Improves the Revised-International Prognostic Index (R-IPI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP

Leyre Bento, MD, Antonia María Bautista-Gili, MD, Francesc García, Jordi Martínez-Serra, PhD, Lucía García-Mañó, MD, Marta García-Recio, MD, Carmen Ballester, MD, Jordi Ginés, MD, Paloma López, MD, Jaime Daumal, Rafael Ramos, MD, Antonio Salar, MD PhD, Antonia Sampol, MD PhD, Juan Besalduch, MD PhD, Antonio Gutiérrez, MD PhD

Blood (2015) 126 (23): 2654.

https://doi.org/10.1182/blood.V126.23.2654.2654

Published: 2015

Journal Articles

Clinical Results of Gemox-R in Mantle CELL Lymphoma: The Role of Oxaliplatin

Marta García-Recio, MD, Antonio Gutierrez, MD PhD, Antonia Obrador-Hervia, PhD, Lucia García Mañó, MD, Leyre Bento, MD, Juan Besalduch, MD PhD, Jose Rodriguez, MD PhD, Antonia Sampol, Priam Villalonga, PhD, Silvia Fernandez, PhD

Blood (2015) 126 (23): 2722.

https://doi.org/10.1182/blood.V126.23.2722.2722

Published: 2015

Journal Articles

Differential Impact of Relative Dose-Intensity Reductions (DIR) in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP21 or R-CHOP14

Leyre Bento, MD, Francesc Garcia, PhD, Antonia Maria Bautista-Gili, Blanca Sanchez, Lucia Garcia, MD, Eva Gimeno, Jordi Martinez-serra, PhD, Mariana Ferraro, Raquel Del campo, Javier Vercher, Miguel Scaff, Ana Pacheco, Florencia Garcia, Rafael Ramos, MD, Carmen Ballester, Juan Besalduch, MD PhD, Joan Bargay, MD, Antonio Salar, MD, Antonio Gutierrez, MD PhD

Blood (2014) 124 (21): 3073.

https://doi.org/10.1182/blood.V124.21.3073.3073

Published: 2014

Journal Articles

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Blood (2014) 124 (21): 3457.

https://doi.org/10.1182/blood.V124.21.3457.3457

Published: 2014

Journal Articles

Impact Of Dose-Density Delays In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-CHOP21 Or R-CHOP14

Antonio Gutierrez, MD, PhD, Antonia M Bautista-Gili, MD, Leyre Bento, MD, Ines Herraez, MD, Lucia Garcia, MD, Jordi Martinez-serra, PhD, Antonia Sampol, MD, PhD, Rafael Ramos, MD, Jordi Gines, MD, Carmen Ballester, MD, Albert Perez, MD, Paloma Lopez-Perezagua, MD, Jaime Daumal, MD, Jose Rodriguez, MD, PhD, Juan Besalduch, MD, PhD

Blood (2013) 122 (21): 4374.

https://doi.org/10.1182/blood.V122.21.4374.4374

Published: 2013

Journal Articles

The Impact Of European Leukemia Net (ELN) Genetic Classification On The Outcome Of Allogeneic Stem Cell Transplantation (ALLOHCT) For Acute Myeloid Leukemia (AML) In First Complete Remission

Blood (2013) 122 (21): 2107.

https://doi.org/10.1182/blood.V122.21.2107.2107

Published: 2013

Journal Articles

Radiotherapy Overcomes Adverse Prognostic Role Of COX-2 Expression On Reed-Sternberg Cells In Early Hodgkin Lymphoma

Antonio Gutierrez, MD, PhD, Mestre Francesc, MD, Jose Rodriguez, MD, PhD, Jordi Martinez-serra, PhD, Rafael Ramos, MD, Ines Herraez, MD, Antonia M Bautista-Gili, MD, Leyre Bento, MD, Lucia Garcia, MD, Jordi Gines, MD, Teresa Ros, Albert Perez, MD, Paloma Lopez-Perezagua, MD, Jaime Daumal, MD, Juan Besalduch, MD, PhD

Blood (2013) 122 (21): 1757.

https://doi.org/10.1182/blood.V122.21.1757.1757

Published: 2013

Journal Articles

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Blood (2012) 120 (21): 334.

https://doi.org/10.1182/blood.V120.21.334.334

Published: 2012

Journal Articles

Gemcitabine and Oxaliplatinum (GemOx): An Effective Regimen in Patients with Refractory and Relapsing Hodgkin Lymphoma

Antonio Gutierrez, MD, PhD, Jose Rodriguez, Andres Lopez, Jordi Martinez-serra, Jorge Gines, María Pilar Paredes, Florencia Garcia, Javier Vercher, Josep Balanzat, Raquel Del campo, Pilar Galan, Miguel Morey, Joan Bargay, Juan Besalduch, MD, PhD

Blood (2012) 120 (21): 4845.

https://doi.org/10.1182/blood.V120.21.4845.4845

Published: 2012

Journal Articles

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Blood (2011) 118 (21): 3962.

https://doi.org/10.1182/blood.V118.21.3962.3962

Published: 2011

Journal Articles

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, José Ramón González, MD, PhD, Alicia Bailen, MD, Jose F Falantes, MD, Joaquin Sanchez, MD, Rafael F Duarte, Juan Besalduch, MD, Andreu Lapiedra, MD

Blood (2009) 114 (22): 4835.

https://doi.org/10.1182/blood.V114.22.4835.4835

Published: 2009

Journal Articles

Expression of COX-2 Is An Independent Unfavourable Prognostic Factor in Hodgkin Lymphoma Treated with ABVD with or without Radiotherapy.

Francisco Mestre, Antonio Gutierrez, MD, Rafael Ramos, Jordi Martinez-Serra, Antonia Bautista, José Fuster, Pilar Lopez-Marti, Marta Casasus, Cristina Nicolau, Julio Rifa, Juan Besalduch, MD, Juan Fernando Garcia, Jose Rodriguez

Blood (2009) 114 (22): 1560.

https://doi.org/10.1182/blood.V114.22.1560.1560

Published: 2009

Journal Articles

Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study

Blood (2008) 112 (11): 161.

https://doi.org/10.1182/blood.V112.11.161.161

Published: 2008

Journal Articles

Therapeutic Angiogenesis in Critical Limb Ischemia by Implantation of Autologous Hematopoietic Cells.

Juan Besalduch, MD, PhD, Raul Lara, MD, Antonia Sampol, MD, Antonio Gutierrez, MD, Pacual Lozano, MD, Antonio Galmes, MD; PhD

Blood (2005) 106 (11): 4222.

https://doi.org/10.1182/blood.V106.11.4222.4222

Published: 2005

Journal Articles

Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML).

Blood (2004) 104 (11): 398.

https://doi.org/10.1182/blood.V104.11.398.398

Published: 2004

NARROW

Addition of Absolute Lymphocytes/Monocytes Ratio Improves the Revised-International Prognostic Index (R-IPI) in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP

Clinical Results of Gemox-R in Mantle CELL Lymphoma: The Role of Oxaliplatin

Differential Impact of Relative Dose-Intensity Reductions (DIR) in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP21 or R-CHOP14

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Impact Of Dose-Density Delays In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-CHOP21 Or R-CHOP14

The Impact Of European Leukemia Net (ELN) Genetic Classification On The Outcome Of Allogeneic Stem Cell Transplantation (ALLOHCT) For Acute Myeloid Leukemia (AML) In First Complete Remission

Radiotherapy Overcomes Adverse Prognostic Role Of COX-2 Expression On Reed-Sternberg Cells In Early Hodgkin Lymphoma

Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial

Gemcitabine and Oxaliplatinum (GemOx): An Effective Regimen in Patients with Refractory and Relapsing Hodgkin Lymphoma

A Phase III PETHEMA/GEM Randomized Trial of Postransplant (ASCT) Maintenance in Multiple Myeloma: Superiority of Bortezomib/Thalidomide Compared with Thalidomide and Alfa-2b Interferon,

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Expression of COX-2 Is An Independent Unfavourable Prognostic Factor in Hodgkin Lymphoma Treated with ABVD with or without Radiotherapy.

Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study

Therapeutic Angiogenesis in Critical Limb Ischemia by Implantation of Autologous Hematopoietic Cells.

Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only